- Home
- UPXI vs ABVC Comparison
UPXI vs ABVC Comparison
Compare UPXI & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | ABVC |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 50.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UPXI | ABVC |
|---|---|---|
| Price | $0.72 | $1.64 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 56.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $141.57 | $735.18 |
| Revenue Next Year | $14.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.46 |
| 52 Week High | $22.57 | $5.48 |
Technical Indicators
Market Signals| Indicator | UPXI | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 20.89 | 31.13 |
| Support Level | $0.71 | $1.53 |
| Resistance Level | $2.05 | $1.76 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 1.09 | 15.79 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.